Quick Answer
Connect Biopharma Holdings Ltd reported Cash and Equivalents of $38.34 million for fiscal year 2025.
Connect Biopharma Holdings Ltd Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $38.34M | -51.0% |
| 2024 | $78.23M | -26.0% |
| 2023 | $105.66M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $37.84M | — | -6.9% |
| June 30, 2025 | $40.63M | — | -14.8% |
| March 31, 2025 | $47.71M | — | -39.0% |
| December 31, 2024 | $78.23M | — | — |
- Connect Biopharma Holdings Ltd showed a decrease of -51.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2023–2025 period, Connect Biopharma Holdings Ltd’s cash and equivalents has declined by 63.7% (from $105.66 million to $38.34 million).
- The most recent figure is from Connect Biopharma Holdings Ltd’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: